AngioDynamics Inc (ANGO)vsJohnson & Johnson (JNJ)
ANGO
AngioDynamics Inc
$12.13
-1.06%
HEALTHCARE · Cap: $479.00M
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 30429% more annual revenue ($99.33B vs $325.38M). JNJ leads profitability with a 16.2% profit margin vs -10.1%. ANGO appears more attractively valued with a PEG of 1.41. JNJ earns a higher WallStSmart Score of 57/100 (C).
ANGO
Hold40
out of 100
Grade: D
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+38.2%
Fair Value
$18.39
Current Price
$12.13
$6.26 discount
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -20.1% — below average capital efficiency
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ANGO
The strongest argument for ANGO centers on Debt/Equity. PEG of 1.41 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : ANGO
The primary concerns for ANGO are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ANGO profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
ANGO carries more volatility with a beta of 0.30 — expect wider price swings.
ANGO is growing revenue faster at 6.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 40/100), backed by strong 16.2% margins. ANGO offers better value entry with a 38.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AngioDynamics Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
AngioDynamics, Inc. designs, manufactures and sells various medical, surgical and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company is headquartered in Latham, New York.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?